Cyclobenzaprine Hydrochloride
Product Images NDC 53002-0521

4 FDA label images from Rpk Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 53002-0521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)
Chemical structure of Cyclobenzaprine Hydrochloride, showing the molecular arrangement of the active ingredient including its aromatic rings and hydrochloride component.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
A table comparing the incidence of side effects including drowsiness, dry mouth, fatigue, and headache across three groups: Cyclobenzaprine HCl Tablets 5 mg (N=464), Cyclobenzaprine HCl Tablets 10 mg (N=249), and Placebo (N=469). The percentages of each side effect are listed for each group.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
A table comparing the incidence percentages of drowsiness, dry mouth, and dizziness in clinical studies and a surveillance program for Cyclobenzaprine Hydrochloride 10 mg tablets. The clinical studies show 39% drowsiness, 27% dry mouth, and 11% dizziness, while the surveillance program reports 16% drowsiness, 7% dry mouth, and 3% dizziness.*
FDA Label Image

Label Image (Lbl530020521)

Label Image (Lbl530020521)
Cyclobenzaprine Hydrochloride 5 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label includes dosing instructions to take one tablet three times a day as needed or as directed. The package contains 30 tablets and shows prescription-only designation with the NDC number 53002-0521. The label includes spaces for clinic name, patient name, and dates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.